DECIPHERA

ROBUST PIPELINE OF SWITCH-CONTROL KINASE INHIBITORS



Notes: CSF1R=colony-stimulating factor 1 receptor; GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; PDGFRA=platelet-derived growth factor receptor α; RAS=rat sarcoma gene; TIE2=TEK tyrosine kinase; TGCT=tenosynovial giant cell tumor; ULK=unc-51-like kinase; (1) European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of QINLOCK (ripretinib) for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib; (2) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (3) QINLOCK is approved for 4th line GIST in the United States, Australia, Canada, China, Hong Kong, Switzerland, and Taiwan; (4) Represent planned 2021-2022 milestones; (5) Subject to discussions with health authorities.